Albumin-bilirubin grade as a prognostic factor of hepatocellular carcinoma after treatment with orthotopic liver transplantation

白蛋白-胆红素分级作为原位肝移植治疗后肝细胞癌的预后因素

阅读:1

Abstract

BACKGROUND: Hepatic function restoration is the main process taking place after liver transplantation. Albumin-bilirubin (ALBI) grade is a new tool for assessing the severity of liver dysfunction. This evidence-based model is solely based on serum bilirubin and albumin levels, which could help clinicians obtain a more objective scale that guides disease diagnosis and treatment. METHODS: Total bilirubin levels, albumin amounts, and other biochemical indicators were determined in a total of 75 adult patients who underwent orthotopic liver transplantation (OLT) for HCC. The aim of the present study was to assess the prognostic value of the ALBI grade in patients with hepatocellular carcinoma (HCC). RESULTS: Median total bilirubin at the time of transplantation was 18.20 µmol/L (range, 12.50-43.63), while median albumin was 40.10 g/L (range, 35.21-44.17). Among the assessed patients, 27 (36.0%) experienced HCC recurrence after OLT and 23 (30.7%) died during follow-up. Patients with ALBI grade 1 had a survival advantage over those of other grades. ALBI grade 1 predicted the better post-operative overall survival (OS) and recurrence-free survival (RFS) in HCC patients after OLT [HR =3.095 (1.290-7.426), P=0.011; HR =3.967 (1.640-9.597), P=0.002, respectively]. In multivariate logistic regression analysis, ALBI grade (grade 1 vs. grades 2 and 3) was a significant independent prognostic factor of HCC recurrence after OLT [OR =6.842 (1.550-30.199), P=0.011]. CONCLUSIONS: Our findings indicated that ALBI grade is a potential predictor of both OS and RFS, representing an independent prognostic marker of HCC following OLT, improving the preoperative liver function status may promote the prognosis of patients with HCC after OLT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。